Qiagen (QGEN) Price Target Cut to $37.00

Qiagen (NYSE:QGEN) had its target price cut by equities researchers at Morgan Stanley from $39.00 to $37.00 in a report issued on Wednesday, Stock Target Advisor reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 13.57% from the stock’s previous close.

Separately, DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a research report on Thursday, April 5th.

How to Become a New Pot Stock Millionaire

Qiagen stock opened at $32.58 on Wednesday. Qiagen has a 52-week low of $27.83 and a 52-week high of $36.34. The company has a quick ratio of 4.59, a current ratio of 5.07 and a debt-to-equity ratio of 0.69. The stock has a market cap of $7,312.62, a price-to-earnings ratio of 25.17, a PEG ratio of 1.98 and a beta of 1.02.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.01. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The firm had revenue of $396.86 million for the quarter, compared to analysts’ expectations of $394.48 million. sell-side analysts expect that Qiagen will post 1.34 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Qiagen (QGEN) Price Target Cut to $37.00” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://weekherald.com/2018/04/13/qiagen-qgen-price-target-cut-to-37-00.html.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Stock Target Advisor

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply